Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.54 |
| ▸ | NMUR1 | Q9HB89 | 2/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 10/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.52 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.51 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22871635 | 0.95 | OPRM1 (0.52) | NMUR2NMUR1OPRM1OPRK1OPRD1 | |
| SCHEMBL21318194 | 0.94 | NMUR2 (0.51) | NMUR2NMUR1OPRM1OPRK1OPRD1 | |
| SCHEMBL20173734 | 0.91 | OPRM1 (0.54) | NMUR2NMUR1OPRM1OPRK1OPRD1 | |
| SCHEMBL20173727 | 0.90 | OPRM1 (0.54) | NMUR2NMUR1OPRM1OPRK1F2 | |
| SCHEMBL20173779 | 0.86 | KMT2A (0.48) | F2PRSS1 | |
| SCHEMBL22871631 | 0.85 | ITGB3 (0.53) | NMUR2NMUR1OPRM1OPRK1OPRD1 | |
| SCHEMBL20173872 | 0.84 | REN (0.59) | OPRK1 | |
| SCHEMBL20174122 | 0.83 | OPRK1 (0.61) | NMUR2NMUR1OPRM1OPRK1OPRD1 | |
| SCHEMBL22962005 | 0.82 | F2 (0.58) | OPRM1OPRD1F2PRSS1 | |
| SCHEMBL17553458 | 0.82 | PAX8 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10889543-B2 | Fine-tune modulators of neuronal excitability for neuropsychiatric disorders | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-01-12 | — | — | US | disclosed |
| US-20190270705-A1 | FINE-TUNE MODULATORS OF NEURONAL EXCITABILITY FOR NEUROPSYCHIATRIC DISORDERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-09-05 | — | — | US | disclosed |
| WO-2018094335-A1 | FINE-TUNE MODULATORS OF NEURONAL EXCITABILITY FOR NEUROPSYCHIATRIC DISORDERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10889543-B2 | Fine-tune modulators of neuronal excitability for neuropsychiatric disorders | CACNG6, KCNN3, SCN1B | NMUR2 217/4885NMUR1 248/4885OPRM1 587/4885 |
| US-20190270705-A1 | FINE-TUNE MODULATORS OF NEURONAL EXCITABILITY FOR NEUROPSYCHIATRIC DISORDERS | CACNG6, KCNN3, SCN1B | NMUR2 217/4885NMUR1 248/4885OPRM1 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.